Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to examine whether the value of vaginal fluid cytokine levels as well as computerized fetal ECG analysis are suitable clinical parameters to detect an imminent intra-amniotic inflammation with a high risk of fetal inflammatory response syndrome (FIRS) or a neonatal early onset sepsis (EOS) and whether these parameters can be determined on a daily basis in the clinical monitoring of pregnancies complicated by PPROM.


Clinical Trial Description

Preterm premature rupture of membranes (PPROM) is one of the leading causes for preterm birth and adverse neonatal outcome. Between 24 0/7 and 34 0/7 weeks of gestation the prolongation of pregnancy is the recommended course of action to reduce the risks of prematurity in most countries. An intra-amniotic infection resulting in fetal inflammatory response syndrome (FIRS) or early onset neonatal sepsis (EOS) is often associated with high morbidity and mortality.

Standard monitoring includes the maternal response to inflammation (i.e. maternal serum parameters) as well as fetal signs of acute FIRS (i.e. fetal tachycardia, high cytokine level in amniotic fluid obtained by amniocentesis). Changes of fetal ECG-parameters are also a sign of an acute FIRS.

Currently, there is no adequate parameter for the surveillance of a possible ongoing intra-amniotic infection. Other studies have reported a correlation between vaginal fluid interleukine 6 (IL6) collected noninvasively and the risk of FIRS and EOS. Information obtained by computerized fetal ECG analysis might be suitable to detect early signs of fetal infection before the manifestation of FIRS.

With the implementation of a vaginal fluid collector it is possible to detect the vaginal fluid cytokine in clinical everyday routine. With the improvement of fetal ECG monitoring it is possible to record the fetal ECG daily. This study examines the correlation between these new parameters and the onset of fetal infection before the manifestation of a severe systemic fetal inflammation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02702297
Study type Observational
Source Martin-Luther-Universität Halle-Wittenberg
Contact
Status Completed
Phase
Start date January 7, 2016
Completion date November 10, 2018

See also
  Status Clinical Trial Phase
Completed NCT01431248 - PPROM Erythromycin Versus Azithromycin N/A
Active, not recruiting NCT04588220 - Melatonin, Soluble Urokinase-type Plasminogen Activator Receptor, and Orosomucoid 2 Levels in PPROM
Completed NCT02314728 - Cervical Ripening in Premature Rupture of Membranes N/A
Not yet recruiting NCT01152528 - Va-Sense - Bacterial Vaginosis Once A Week Screening And Treatment To Reduce Infective Complications, Abortion And Preterm Delivery In Pregnant Women With Previous Preterm Delivery Phase 3
Not yet recruiting NCT02635451 - The Relation Between Serum Ascorbic Acid Concentration and Preterm Premature Rupture of Membranes N/A
Completed NCT01266928 - Does Vitamins C and E Supplementation of After Preterm Rupture of Membranes Prolong the Duration of Latency? A Prospective Randomized Controlled Study Phase 3
Active, not recruiting NCT04532021 - Matrix Metalloproteinase 14, Neopterin, and Orosomucoid 1 Levels in PPROM
Recruiting NCT02548013 - Preterm Premature Rupture of Membranes, Outpatient Management vs Inpatient Management N/A
Recruiting NCT01584323 - Pomegranate to Reduce Maternal and Fetal Oxidative Stress and Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of the Membranes N/A
Recruiting NCT00466128 - Indomethacin Versus Placebo in Women With Preterm Premature Rupture of Membranes (PPROM) Phase 2
Terminated NCT00463736 - Magnesium Sulfate Versus Placebo for Tocolysis in PPROM N/A